BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29043891)

  • 1. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A; Gaïni S; Sore P
    Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Ro 52 positive dermatomyositis presenting as rapidly progressive interstitial lung disease.
    Conway R; O'Donnell R; Fahy R; Doran MF; Cunnane G; O'Shea FD
    QJM; 2014 Jul; 107(7):593-4. PubMed ID: 24336848
    [No Abstract]   [Full Text] [Related]  

  • 4. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody.
    Honda M; Moriyama M; Kondo M; Kumakura S; Sumita Y; Murakawa Y
    Scand J Rheumatol; 2020 May; 49(3):244-246. PubMed ID: 31571515
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
    Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.
    Zhang X; Zhou S; Wu C; Li M; Wang Q; Zhao Y; Zeng X
    Rheumatology (Oxford); 2021 Jul; 60(7):e227-e228. PubMed ID: 33410494
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
    Chan CWS; Chung HY; Lau CS; Tsang HHL
    Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H; Wong VTL; Lao VWN; Pang HT; Yip RML
    Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B; Merav L; Pnina L; Chagai G
    Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K; Hagino N
    Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vocal cord palsy in refractory anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis.
    Alsaed OS; Alamlih LI; Farfar KA; Mohd TRN; Alemadi SAAR; Malallah HA
    Rheumatology (Oxford); 2020 Oct; 59(10):e66-e67. PubMed ID: 32252065
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
    Matsumoto H; Sato S; Fujita Y; Yashiro-Furuya M; Matsuoka N; Asano T; Kobayashi H; Watanabe H; Migita K
    Intern Med; 2019 Mar; 58(5):737-742. PubMed ID: 30333415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.